{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:09:34Z","timestamp":1790467774702,"version":"4.1.0"},"reference-count":44,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,11,13]],"date-time":"2012-11-13T00:00:00Z","timestamp":1352764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:p>\n                    <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\u2022\u2003It has generally been regarded as safe to take erythromycin during pregnancy. A recent study from Sweden found that erythromycin exposure in the first trimester was associated with congenital cardiovascular defects. The results led to warnings against using erythromycin in the first trimester from both the Swedish and Norwegian governments.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\u2022\u2003This large, population\u2010based register study did not find that erythromycin or macrolide use in pregnancy was significantly associated with congenital malformations, cardiovascular malformations or any other specific malformation.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>AIMS<\/jats:bold>\n                    Erythromycin is a macrolide antibiotic indicated for respiratory tract infections, genital chlamydia and skin infections. It has recently been suggested that erythromycin use in the first trimester of pregnancy can increase the risk of congenital cardiovascular malformations. This study aimed to determine whether erythromycin exposure in the first trimester is associated with cardiovascular or other malformations.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>METHODS<\/jats:bold>\n                    We studied 180\u2003120 women in Norway who were pregnant during 2004\u20132007. Data on all live births stillbirths and induced abortions after 12 gestational weeks from The Medical Birth Registry of Norway (MBRN) were linked to information from the Norwegian prescription database (NorPD). We compared the pregnancy outcomes of women who had taken erythromycin (\n                    <jats:italic>n<\/jats:italic>\n                    = 1786, 1.0%), penicillin V (\n                    <jats:italic>n<\/jats:italic>\n                    = 4921, 2.7%) or amoxicillin (\n                    <jats:italic>n<\/jats:italic>\n                    = 1599, 0.9%) in their first trimester with outcomes of women who had not taken any systemic antibiotics (\n                    <jats:italic>n<\/jats:italic>\n                    = 163\u2003653, 90.9%) during this period.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS<\/jats:bold>\n                    The risk of cardiovascular malformations was not significantly different with or without exposure to erythromycin in the first trimester (adjusted OR = 1.2 [95% CI 0.8, 1.8]) or in the most vulnerable period of heart formation (adjusted OR = 1.6 [95% CI 0.9\u20133.0]). Sub\u2010analyses showed that the risk for any specific malformations was not increased with erythromycin, macrolides, penicillin V or amoxicillin compared with no antibiotic use in first trimester.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSIONS<\/jats:bold>\n                    This large, population\u2010based register study did not find that exposure to erythromycin or macrolides in the first trimester of pregnancy was associated with fetal cardiovascular or other malformations. These results suggest that the risk of erythromycin use during early pregnancy, if any, is low.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2125.2012.04286.x","type":"journal-article","created":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T09:21:55Z","timestamp":1333444915000},"page":"1053-1062","source":"Crossref","is-referenced-by-count":48,"title":["Pregnancy outcome after gestational exposure to erythromycin \u2013 a population\u2010based register study from Norway"],"prefix":"10.1111","volume":"74","author":[{"given":"Maria","family":"Rom\u00f8ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Lindb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedvig","family":"Nordeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,11,13]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.04.025"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2006.00927.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03102.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0546-y"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050608"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0b013e3181de8a6f"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2005.11.003"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-011-9586-1"},{"key":"e_1_2_7_10_2","volume-title":"Sexually Transmitted Diseases Treatment Guidelines, 2010","author":"Centers for Disease Control and Prevention","year":"2011"},{"key":"e_1_2_7_11_2","volume-title":"Sexually Transmitted and Other Reproductive Tract Infections. A Guide to Essential Practice","author":"World Health Organization","year":"2005"},{"key":"e_1_2_7_12_2","first-page":"588","volume-title":"Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk, 7th Edition","author":"Briggs GG","year":"2005"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2005.01.010"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2008.05.024"},{"key":"e_1_2_7_15_2","volume-title":"Drugs during Pregnancy","author":"K\u00e4ll\u00e9n BA","year":"2009"},{"key":"e_1_2_7_16_2","unstructured":"Norwegian Medicines Agency.[Drugs during pregnancy][Internet].2007. Norwegian. Available athttp:\/\/www.slv.no\/templates\/InterPage____28568.aspx(last accessed 30 April 2012)."},{"key":"e_1_2_7_17_2","unstructured":"The Swedish Medical Products Agency.[Erythromycin should be avoided in early pregnancy][Internet].2006. Swedish. Available athttp:\/\/www.lakemedelsverket.se\/Alla\u2010nyheter\/NYHETER\u20132005\/Erytromycin\u2010bor\u2010undvikas\u2010under\u2010tidig\u2010graviditet\/(last accessed 30 April 2012)."},{"key":"e_1_2_7_18_2","unstructured":"Therapeutic Goods Administration.Prescribing medicines in pregnancy database [Internet].2012. Department of Health and Ageing Australian Government. Available athttp:\/\/www.tga.gov.au\/hp\/medicines\u2010pregnancy.htm(last accessed 30 April 2012)."},{"key":"e_1_2_7_19_2","unstructured":"Drugs Information Online.Eythromycin Tablets [Internet].2012. Available athttp:\/\/www.drugs.com(last accessed 30 April 2012)."},{"key":"e_1_2_7_20_2","volume-title":"Guidelines for the Management of Sexually Transmitted Infections","author":"World Health Organization","year":"2003"},{"key":"e_1_2_7_21_2","unstructured":"JonesD.Use of erythromycin in pregnancy. [Internet]. UK Teratology Information Service.2009. Available athttp:\/\/www.nelm.nhs.uk\/en\/NeLM\u2010Area\/Evidence\/Drugs\u2010in\u2010Pregnancy\/Use\u2010of\u2010erythromycin\u2010in\u2010pregnancy\/(last accessed 30 April 2012)."},{"key":"e_1_2_7_22_2","unstructured":"Eurocat.Eurocat Special Report. Congenital heart defects in Europe 2000\u20102005. University of Ulster: eurocat central registry.2009. Available athttp:\/\/www.eurocat\u2010network.eu\/content\/Special\u2010Report\u2010CHD.pdf(last accessed 30 April 2012)."},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.627224"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/siny.2000.0032"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.183056"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.183216"},{"key":"e_1_2_7_27_2","volume-title":"Langman's Medical Embryology, 6th Edition","author":"Sadler TW","year":"1990"},{"key":"e_1_2_7_28_2","volume-title":"Guidelines for ATC Classification and DDD Assignment 2011","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2010"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2008.07.008"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2009.188"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0890-6238(99)00046-5"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.538"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-994053"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.119718"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.2174\/157340309788970397"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-007-7211-8"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1027309703313"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/508873"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612013397744"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420500202"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/08037050701645090"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/00016340802217184"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1741-4520.2005.00062.x"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr295"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1080\/00016340903128454"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2012.04286.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2012.04286.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:34:47Z","timestamp":1697427287000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2012.04286.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,13]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1365-2125.2012.04286.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04286.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,13]]}}}